TY - JOUR T1 - Considerations Regarding the Use of Blood Samples in the Proteomic Identification of Biomarkers for Cancer Diagnosis JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 227 LP - 230 VL - 3 IS - 3-4 AU - CHRISTINE V. SAPAN AU - ROGER L. LUNDBLAD Y1 - 2006/05/01 UR - http://cgp.iiarjournals.org/content/3/3-4/227.abstract N2 - Blood is the most common source of biomarkers for use in the diagnosis and prognosis of malignant disease. Utilizing proteomic technology for biomarker identification offers greatly increased sensitivity. Such an increase in sensitivity requires precise sample preparation to eliminate any bias in analysis. Here, issues concerning the use of blood, plasma and serum for proteomic analysis are summarized. ER -